Prospective ligand- and target-based 3D QSAR: State of the art 2008

Current Topics in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 791-810

  Clark, Robert D ^a,b  

^a Biochemical Infometrics   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

3D QSAR; Alignment; Docking; Molecular fields; Pharmacophores; Prospective QSAR; Scoring

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALPHA INTERFERON; B RAF KINASE; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CANNABINOID 1 RECEPTOR; CELL SURFACE RECEPTOR; CHECKPOINT KINASE 1; COAT PROTEIN; DEXTRO ALANINE DEXTRO ALANINE LIGASE; DIHYDROFOLATE REDUCTASE; FARNESOID X RECEPTOR; HISTAMINE H4 RECEPTOR; HORMONE RECEPTOR; HORMONE SENSITIVE LIPASE; LIGAND; LIPOXYGENASE; PHOSPHORIBOSYLTRANSFERASE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE PIM 1; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SEROTONIN 6 RECEPTOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE 17BETA DEHYDROGENASE; THERMOLYSIN; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; PROTEIN;

BINDING SITE; DRUG ACTIVITY; DRUG BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MOLECULAR DOCKING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; THERMODYNAMICS; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; METHODOLOGY; PROTEIN BINDING;

COMPUTER SIMULATION; DRUG DISCOVERY; LIGANDS; PROTEIN BINDING; PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73449105806     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789207118     Document Type: Review

References (280)

1. Blum, A.; Böttcher, J.; Heine, A.; Klebe, G.; Diederich, W. E. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold. J. Med. Chem. 2008, 51, 2078-2087. [2] Laufer, S. A.; Hauser, D. R. J.; Domeyer, D. M.; Kinkel, K.; Liedtke, A. J. Design, synthesis, and biological evaluation of novel tri- and tetra-substituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. J. Med. Chem. 2008, 51, 4122-4149.
2. Chao, E. Y.; Caravella, J. A.; Watson, M. A.; Compobasso, N.; Ghisletti, G.; Billin, A. N.; Galardi, C.; Wang, P.; Lafitte, B. A.; Iannone, N. A.; Goodwin, B. J.; Nichols, J. A.; Parks, D. J.; Stewart, E.; Wiethe, R. W.; Williams, S. P.; Smallwood, A.; Pearce, B. H.; Glass, C. K.; Wilson, T. M.; Zuercher, W. J.; Collins, J. L. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J. Med. Chem. 2008, 51, 5758-5765.
3. Salaniwal, S.; Manas, E. S.; Alvarez, J. C.; Unwalla, R. J. Critical evaluation of merthds to incorporate entropy loss upon binding in high-throughput docking. Proteins 2007, 66, 422-435.
4. Waszkowycz, B. Towards improving compound selection in structure-based virtual screening. Drug Discov. Today 2008, 13, 219-226.
5. Amaro, R. E.; Baron, R.; McCammon, J. A. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput. Aided Mol. Des. 2008, 22, 693-705.
6. Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. 2006, 49, 5851-5855.
7. Güner, O. F., Ed. Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, CA, 2000.
8. Sprague, P. W. Automated chemical hypothesis, generation and database searching with Catalyst. Persp. Drug Disc. Des. 1995, 3, 1-20.
9. Homer, R. W.; Swanson, J.; Jilek, R. J.; Hurst, T.; Clark, R. D. (2008). SYBYL line notation (SLN): A single notation to represent chemical structures, queries, reactions, and virtual libraries. J. Chem. Inf. Model. 2008, 48, 2294-2307.
10. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today 2008, 13, 23-29.
11. Rush, T. S. III; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 2005, 48, 1489-1495.
12. Jain, A. N. Ligand-based structural hypotheses for virtual screening. J. Med. Chem. 2004, 47, 947-961.
13. Hawkins, P. C. D.; Skillman, A. G.; Nicholls, A. Comparison of shape-matching and docking as virtual screening tools. J. Med. Chem. 2007, 50, 74-82.
14. Gillner, M.; Greenidge, P. The use of multiple excluded volumes derived from X-ray crystallographic structures in 3D database searching and 3D QSAR. In Pharmacophore Perception, Development, and Use in Drug Design, Güner, O., Ed.; International University Line: La Jolla, CA, 1999; pp. 373-384.
15. Langer, T.; Hoffmann??, R.D. Pharmacophore modelling: applications in drug discovery. Exp. Opin. Drug Discov. 2006, 1, 261-267.
16. Cramer, R. D. III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
17. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
18. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE) : an advanced chemometric tool for handling 3D-QSAR problems. QSAR Comb. Sci. 1993, 12, 9-20.
19. Coupez, B.; Lewis, R. A. Docking and scoring: Theoretically easy, practically impossible? Curr. Med. Chem. 2006, 13, 2995-3003.
20. Good, A. C.; Rajamani, R. Ranking poses in structure-based lead discovery and optimization: Current trends in scoring function development. Curr. Opin. Drug Discov. Devel. 2007, 10, 308-315.
21. Willett, P. A bibliometric analysis of the literature of chemoinformatics. Aslib Proc. 2008, 60, 4-17.
22. Gund, P. Three-dimensional pharmacophoric pattern searching. Prog. Mol. Subcell. Biol. 1977, 5, 117-43.
23. Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. The conformational parameter in drug design: the active analogue approach in computer-assisted drug design. In: Computer-Assisted Drug Design; Olson, E. C., Christoffersen, R. E., Eds; American Chemical Society: Washington DC, 1979; Vol. 112, pp. 205-226.
24. Willett, P. From chemical documentation to chemoinformatics: 50 years of chemical information science. J. Inf. Sci. 2008, 34, 477-499.
25. Tsuchida, K.; Chaki, H.; Takakura, T.; Kotsubo, H.; Tanaka, T.; Aikawa, Y.; Shiozawa, S.; Hirono, S. Discovery of nonpeptide small molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model. J. Med. Chem. 2006, 49, 80-91.
26. Deng, J.; Sanchez, T.; Neamati, N.; Briggs, J.M. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. J. Med. Chem. 2006, 49, 1684-1692.
27. Martin, M. W.; Newcomb, J.; Nunes, J. J.; Boucher, C.; Chai, L.; Epstein, L. F.; Faust, T.; Flores, S.; Gallant, P.; Gore, A.; Gu, Y.; Hsieh, F.; Huang, X.; Kim, J. L.; Middleton, S.; Morgenstern, K.; Oliveira-dos-Santos, A.; Patel, V. F.; Powers, D.; Rose, P.; Tudor, Y.; Turci, S. M.; Welcher, A.A.; Zack, D.; Zhao, H.; Zhu, L.; Zhu, X.; Ghiron, C.; Ermann, M.; Johnston, D.; Saluste, C.-G. P. Structure-based design of novel 2-amino-6-phenyl-pyramido [5′,4′:5,6]pyramido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SA, and in vivo anti-inflammatory activity. J. Med. Chem. 2008, 51, 1637-1648.
28. Pierce, A. C.; Jacobs, M.; Stuver-Moody, C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J. Med. Chem. 2008, 51,1972-1975.
29. Kiss, R.; Kiss, B.; Könczöl, Á.; Szalai, F.; Jelinek, F.; Lázló, V.; Noszál, B.; Falus, A.; Keserú, G. M. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J. Med. Chem. 2008, 51, 3145-3153.
30. Gundla, R.; Kazemi, R.; Sanam, R.; Muttineni, R.; Sarma, J. A. R. P.; Dayam, R,; Neamati, N. Discovery of novel small-molecule inhibitors of epidermal growth factor receptor-2: combined ligand and target-based approach. J. Med. Chem. 2008, 51, 3367-3377.
31. Charifson, P. S.; Grillot, A.-L.; Grossman, T. H.; Parsons, J. D.; Badia, M.; Bellon, S.; Deininger, D. D.; Drumm, J. E.; Gross, C. H.; LeTiran, A.; Liao, Y.; Mani, N.; Nicolau, D. P.; Perola, E.; Ronkin, S.; Shannon, D.; Swenson, L. L.; Tang, Q.; Tessier, P. R.; Tian, S.-K.; Trudeau, M.; Wang, T.; Wei, Y.; Zhang, H.; Stamos, D. Novel dual-acting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J. Med. Chem. 2008, 51, 5243-5263.
32. Zheng, S.; Kaur, G.; Wang, H.; Li, M.; Macnaughton, M.; Yang, X.; Reid, S.; Prestegard, J.; Wang, B.; Ke, H. Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors. J. Med. Chem. 2008, 51, 7673-7688.
33. Wei, D.; Jiang, X.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J.; Lai, L. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 2008, 51, 7882-7888.
34. Sabio, M.; Jones, K.; Topiol, S. Use of the X-ray structure of the β2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Biorg. Med. Chem. Lett. 2008, 18, 5391-5395.
35. Hadac, E. M.; Dawson, E. S.; Darrow, J. W.; Sugg, E. E.; Lybrand, T. P.; Miller, L. J. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J. Med. Chem. 2006, 49, 850-863.
36. Raitio, K. H.; Savinainen, J. R.; Vepsäläinen, J.; Laitinen, J. T.; Poso, A.; Järvinen, T.; Nevalainen, T. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. J. Med. Chem. 2006, 49, 2022-2027.
37. Heikkilä, T.; Ramsey, C.; Davies, M.; Galtier, C.; Stead, A. M. W.; Johnson, A. P.; Fishwick, C. W. G.; Boa, A. N.; McConkey, G. A. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J. Med. Chem. 2007, 50, 186-191.
38. Käpylä, J.; Pentikäinen, O. T.; Nyrönen, T.; Nissinen, L.; Lassander, S.; Jokinen, J.; Lahti, M.; Marjamäki, A.; Johnson, M. S.; Heino, J. Small molecule designed to target metal binding site in the α2I domain inhibits integrin function. J. Med. Chem. 2007, 50, 2742-2746.
39. Hynes, J. Jr.; Dyckman, A. J.; Lin, S.; Wrobleski, S. T.; Wu, H.; Gilooly, K. M.; Kanner, S. B.; Lonial, H.; Loo, D.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Shuster, D. J.; Yang, X.; Zhang, R.; Behnia, K.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Tokarski, J. S.; Sack, J. S.; Pokross, M.; Kiefer, S. E.; Newitt, J. A.; Barrish, J. C.; Dodd, J.; Schieven, G. L.; Leftheris, K. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α mitogen-activated protein kinase inhibitors. J. Med. Chem. 2008, 51, 4-16.
40. Kakuta, H.; Zheng, X.; Oda, H.; Harada, S.; Sugimoto, Y.; Sasaki, K.; Tai, A. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 inhibitor. J. Med. Chem. 2008, 51, 2400-2411.
41. Frey, R. R.; Curtin, M. L.; Albert, D. H.; Glasr, K. B.; Pease, L. J.; Soni, N. B.; Bouska, J. J.; Reuter, D.; Stewart, K. D.; Marcotte, P.; Bukofzer, G.; Li, J.; Davidsen, S. K.; Michaelides, M. R. 7-Aminopyrazolo[1,5-a] pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 2008, 51, 3777-3787.
42. Kim, Y. A.; Sharon, A.; Chu, C. K.; Rais, R. H.; Safarjalani, A.; Naguib, F. N. M.; el Kouni, M. H. Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase. J. Med. Chem. 2008, 51, 3934-3945.
43. Tomizawa, M.; Kagabu, S.; Ohno, I.; Durkin, K. A.; Casida, J. E. Potency and selectivity of trifluoroacetylimino and pyrazinoylimino nicotinic insecticides and their fit into a unique binding site. J. Med. Chem. 2008, 51, 4213-4218.
44. Seitzberg, J. G.; Knapp, A. E.; Lund, B. W.; Bertozzi, S. M.; Currier, E. A.; Ma, J.-N.; Sherbukhin, V.; Burstein, E. S.; Olsson, R. Discovery of potent and selective small-molecule PAR-2 agonists. J. Med. Chem. 2008, 51, 5490-5493.
45. Chen, J.; Collins, G. T.; Zhang, J.; Yang, C.-Y.; Levant, B.; Woods, J.; Wang, S. Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. J. Med. Chem. 2008, 51, 5905-5908.
46. Martin, R. E.; Green, L. G.; Guba, W.; Kratochwil, N.; Christ, A. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J. Med. Chem. 2007, 50, 6291-6294.
47. Broccolo, F.; Cainelli, G.; Caltabiano, G.; Cocuzza, C. E. A.; Fortuna, C. G.; Galletti, P.; Giacomini, D.; Musumarra, G.; Musumeci, R.; Quintavalla, A. Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria. J. Med. Chem. 2008, 51, 2804-2811.
48. Cullen, M. D.; Deng, B.-L.; Hartman, T. L.; Watson, K. M.; Buckheit, R. W. Jr.; Pannecouque, C.; De Clercq, E.; Cushman, M. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability. J. Med. Chem. 2008, 51, 4854-4867.
49. ACS Publications. Advanced Search. http://pubs.acs.org/ search/ advanced [accessed 14 January 2009].
50. Doweyko, A. M. QSAR: dead or alive? J. Comput.-Aided Mol. Des. 2008, 22, 1573-4951.
51. Scope and editorial policy. J. Med. Chem. 2006, 49, 5A.
52. Güner, O. F., Ed. Special Issue: Advances in Pharmacophores and 3-D Searching. J. Comput.-Aided Mol. Des. 2006, 20(12), 703-802.
53. Stouch, T.; Tropsha, A.; Eds. A Special Issue Honoring Yvonne C. Martin. J. Comput.-Aided Mol. Des. 2007, 21(1-3), 1-144.
54. McMasters, D. R., Ed. Special Issue on ADME and Physical Properties. J. Comput.-Aided Mol. Des. 2007, 21(12), 649-650.
55. Jain, A. N., Nicholls, A., Eds. Special Issue on Evaluation of Computational Methods. J. Comput.-Aided Mol. Des. 2008, 22(3,4), 131-265.
56. Clark, R. D., Ed. Special Issue: Dr. Philip S. Magee Memorial. J. Comput.-Aided Mol. Des. 2008, 22(6,7), 333-521.
57. Reddy, R., Ed. Special Issue on Rational Drug Design. J. Comput.-Aided Mol. Des. 2008, 22(9), 593-705.
58. Bajorath, J. Computational chemistry publications in the Journal of Medicinal Chemistry. J. Med. Chem. 2008, 51, 2327.
59. Rester, U. Dock around the clock - current status of small molecule docking and scoring. QSAR Comb. Sci. 2006, 25, 605-615.
60. Cole, J. C.; Murray, C, W.; Nissink, J. W. M.; Taylor, R. D.; Taylor, R. Comparing protein-ligand docking programs is difficult. Proteins 2005, 60, 325-332.
61. Jain, A. N. Scoring functions for protein-ligand docking. Curr. Protein Pep. Sci. 2006, 7, 407-420.
62. Onodera, K.; Satou, K.; Hirota, H. Evaluations of molecular docking programs for virtual screening. J. Chem. Inf. Model. 2007, 47, 1609-1618.
63. Huang, N.; Shoichet, B.; Irwin, J. J. Benchmarking sets for molecular docking. J. Med. Chem. 2006, 49, 6789-6801.
64. Zsoldos, Z.; Reid, D.; Simon, A.; Sadjad, S. B.; Johnson, A. P. eHiTS: A new fast, exhaustive flexible ligand docking system. J. Mol. Graph. Model. 2007, 26, 198-212.
65. Hassani, M.; Cai, W.; Koelsch, K. H.; Holley, D. C.; Rose, A. S.; Olang, F.; Lineswala, J. P.; Holloway, W. G.; Gerdes, J. M.; Behforouz, M.; Beall, H. D. Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 INQO1) model validation with molecular docking and biological studies. J. Med. Chem. 2008, 51, 3104-3115.
66. de Graaf, C.; Oostenbrink, C.; Keizers, P. H.; van der Wijst, T.; Jongejan, A.; Vermeulen, N. P. E. Catalytic site preparation and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J. Med. Chem. 2006, 49, 2417-2430.
67. Fletcher, S.; Cummings, G. C.; Rivas, K.; Katt, W. P.; Hornéy, C.; Buckner, F. S.; Chakrabarti, D.; Sebti, S. M.; Gelb, M. H.; Van Voorhis, W. C.; Hamilton, A. D. Potent, plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: Structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. J. Med. Chem. 2008, 51, 5176-5197.
68. Lee, S. H.; Seo, H. J.; Lee, S.-H.; Jung, M. E.; Park, J.-H.; Park, H.-J.; Yooo, J.; Yun, H.; Na, J.; Kang, S. Y.; Song, K.-S.; Kim, M.; Chang, C.-H.; Kim, J.; Lee, J. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 2008, 51, 7216-7233.
69. Aparoy, P.; Reddy, R. N.; Guruprasad, L.; Reddy, M. R.; Reddana, P. Homology modeling of 5-lipoxygenase and hints for better inhibitor design. J. Comput.-Aided Mol. Des. 2008, 22, 611-619.
70. Pinto-Bazurco Mendieta Mariano, A.E.; Negri, M.; Jagusch, C.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: Novel CYP17 inhibitors for the treatment of cancer. J. Med. Chem. 2008, 51, 5009-5018.
71. Srivastava, B. K.; Joharapurkar, A.; Raval, S.; Patel, J. Z.; Soni, R.; Raval, P.; Gite, A.; Goswami, A.; Sadhwani, N.; Gandhi, N.; Patel, H.; Mishra, B.; Solanki, M.; Pandey, B.; Jain, M. R.; Patel, P. R. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: Synthesis, biological evaluation, and molecular modeling in the homology model. J. Med. Chem. 2007, 50, 5951-5966.
72. Costanzi, S. On the applicability of GPCR homology models to computer-aided drug discovery: A comparison between in silico and crystal structures of the β2-adrenergic receptor. J. Med. Chem. 2008, 51, 2904-2914.
73. Pérez, E. G.; Cassels, B. K.; Zapata-Torres, G. Molecular modeling of the α9α10 nicotinic acetylcholine receptor subtype. Bioorg. Med. Chem. Lett. 2008, 19, 251-254.
74. Ortore, G.; Tuccinardi, T.; Bertini, S.; Martinelli, A. A theoretical study to investigate D2DAR/D4DAR selectivity: Receptor modeling and molecular docking to dopaminergic ligands. J. Med. Chem. 2006, 49, 1397-1407.
75. Bray, J. K.; Goddard, W. A. III. The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. J. Mol. Graph. Model. 2008, 27, 66-81.
76. Weis, D. C.; Visco, D. P. Jr.; Faulon, J.-L. Data mining PubChem using a support vector machine with the Signature molecular descriptor: Classification of factor XIa inhibitors. J. Mol. Graph. Model. 2008, 27, 466-475.
77. Enyedy, I.; Egan, W. J. Can we use docking and scoring for hit-to-lead optimization? J. Comput.-Aided Mol. Des. 2008, 22, 161-168.
78. Johnson, S. R. The trouble with QSAR (or: How I learned to stop worrying and embrace fallacy). J. Chem. Inf. Model. 2008, 48, 25-26.
79. Boström, J.; Hogner, A.; Schmitt, S. Do structurally similar ligands bind in a similar fashion? J. Med. Chem. 2006, 49, 6716-6725.
80. Guha, R.; Van Drie, J. H. Assessing how well a modeling protocol captures a structure-activity landscape. J. Chem. Inf. Model. 2008, 48, 1716-1728.
81. Doweyko, A. M. 3D-QSAR illusions. J. Comput.-Aided Mol. Des. 2004, 18, 587-596.
82. Roche, O.; Kiyama, R.; Brooks, C. L. III. Ligand-protein database: Linking protein-ligand complex structures to binding data. J. Med. Chem. 2001, 44, 3592-3598.
83. Wang, R.; Fang, X.; Lu, Y.; Yang, C.-Y.; Wang, S. The PDBbind database: Methodologies and updates. J. Med. Chem. 2005, 48, 4111-4119.
84. Tetko, I. V.; Sushko, I.; Pandey, A. K.; Zhu, H.; Tropsha, A.; Papa, E.; Öberg, T.; Todeschini, R.; Fourches, D.; Varnek, A. Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: Focusing on applicability domain and overfitting by variable selection. J. Chem. Inf. Model. 2008, 48, 1733-1746.
85. Williams, A. J. A perspective of publicly accessible/open-access chemistry databases. Drug Discov. Today 2008, 13, 495-501.
86. DTP - Diversity Set Information. http://dtp.nci.nih.gov/branches/dscb/ diversity-explanation.html [Accessed Dec 3, 2008].
87. Irwin, J. J.; Shoichet, B. K. ZINC-A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 58, 177-182.
88. Warren, G. L.; Andrews, W.; Capelli, A.-M.; Clarke, B.; LaLonde, J.; Lambert M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49, 5912-5931.
89. Rao, S. N.; Head, M. S.; Kulkarni, A.; LaLonde, J. M. Validation studies of the site-directed docking program LibDock. J. Chem. Inf. Model. 2007, 47, 2159-2171.
90. Wang, B.; Westerhoff, L. M.; Merz, K. M. Jr. A critical assessment of the performance of protein-ligand scoring functions based on NMR chemical shift perturbations. J. Med. Chem. 2007, 50, 5128-5134.
91. Ciustea, M.; Silverman, J. E. Y.; Shudofsky, A. M. D.; Ricciardi, R. P. Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening. J. Med. Chem. 2008, 51, 6563-6570.
92. McGaughey, G. B.; Sheridan, R. P.; Bayly, C. I.; Culberson, J. C.; Kreatsoulas, C.; Lindsley, S.; Maiorov, V.; Truchon, J.-F.; Cornell, W. D. Comparison of topological, shape, and docking methods in virtual screening. J. Chem. Inf. Model. 2007, 47, 1504-1519.
93. Babaoglu, K.; Simeonov, A.; Irwin, J. J.; Nelson, M. E.; Feng, B.; Thomas, C. J.; Cancian, L.; Costi, M. P.; Maltby, D. A.; Jadhav, A.; Inglese, J.; Austin, C. P.; Shoichet, B. K. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase. J. Med. Chem. 2008, 51, 2502-2511.
94. Sutherland, J. J.; Higgs, R. E.; Watson, I.; Vieth, M. Chemical fragments as foundations for understanding target space and activity prediction. J. Med. Chem. 2008, 51, 2689-2700.
95. Sheridan, R. P.; McGaughey, G. B.; Cornell, W. D. Multiple protein structures and multiple ligands: Effects on the apparent goodness of virtual screening results. J. Comput.-Aided Mol. Des. 2008, 22, 257-265.
96. Cox, E. D.; Diaz-Arauzo, H.; Huang, Q.; Reddy, M. S.; Ma, C.; Harris, B.; McKernan, R.; Skilnoick, P.; Cook, J. M. Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-β-carboline-3- carboxylic acid ethyl ester (6PBC) and the full agonisty 6-(benzyloxy)-4- (methoxymethyl)-β-carboline-3-carboxylic acid ethyl ester (Zk 93423) at wild type and recombinant GABAA receptors. J. Med. Chem. 1998, 41, 2537-2552.
97. Llorens, O.; Perez, J. J.; Palomer, A.; Mauleon, D. Differential binding mode of diverse cyclooxygenase inhibitors. J. Mol. Graph. Model. 2002, 20, 359-371.
98. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, P. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 1999, 42, 5100-5109.
99. Clark, R. D.; Strizhev, A.; Leonard, J.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graph. Model. 2002, 20, 281-295.
100. Verdonk, M. L.; Berdini, V.; Hartshorn, M. J.; Mooij, W. T. M.; Murray, C. W.; Taylor, R. D.; Watson, P. Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J. Chem. Inf. Comput. Sci. 2004, 44, 792-806.
101. Zhang, Q.; Muegge, I. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J. Med. Chem. 2006, 49, 1536-1548.
102. Klon, A. E.; Glick, M.; Davies, J. W. Combination of a naïve Bayes classifier with consensus scoring improves enrichment of high-throughput docking results. J. Med. Chem. 2004, 47, 4356-4359.
103. Montes, M.; Braud, E.; Miteva, M. A.; Goddard, M.-L.; Mondésert, O.; Kolb, S.; Brun, M.-P.; Ducommun, B.; Garbay, C.; Villoutreix, B. O. Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. J. Chem. Inf. Model. 2008, 48, 157-165.
104. Cozza, G.; Bonvini, P.; Zorzi, E.; Poletto, G.; Pagano, M. A,; Sarno, S.; Donella-Deana, A.; Zagatto, G.; Rosolen, A,; Pinna, L. A.; Meggio, F.; Moro, S. Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application. J. Med. Chem. 2006, 49, 2363-2366.
105. Garcia-Sosa, A. T.; Sild, S.; Maran, U. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J. Chem. Inf. Model. 2008, 48, 2074-2080.
106. Wolf, A.; Zimmermann, M.; Hofmann-Apitius, M. Alternative to consensus scoring - A new approach toward the qualitative combination of docking algorithms. J. Chem. Inf. Model. 2007, 47, 1036-1044.
107. Fernández, A. Is there a case for selectively promiscuous anticancer drugs? Drug. Discov. Today 2009, 14, 1-5.
108. Brown, D. A.; Kharkar, P. S.; Parrington, I.; Reith, M. E. A.; Dutta, A. K. Structurally constrained derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: Binding characterization at D2/D3 receptors and elucidation of a pharmacophore model. J. Med. Chem. 2008, 51, 7806-7819.
109. Bamborough, P.; Drewry, D.; Harper, G.; Smith, G. K.; Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 2008, 51, 7896-7914.
110. Ananthula, R. S.; Ravikumar, M.; Pramod, A. B.; Madala, K. K.; Mahmood, S. K. Strategies for generating less toxic P-selectin inhibitors: Pharmacophore modeling, virtual screening and counter pharmacophore screening to renmove toxic hits. J. Mol. Graph. Model. 2008, 27, 546-557.
111. Sykes, M. J.; McKinnon, R. A.; Miners, J. O. Prediction of metabolism by cytochrome P450 2C9: Alignment and docking studies of a validated database of substrates. J. Med. Chem. 2008, 51, 780-791.
112. Crespo, A.; Zhang, X.; Fernández, A. Redesigning kinase inhibitors to enhance specificity. J. Med. Chem. 2008, 51, 4890-4898.
113. Sato, T.; Matsuo, Y.; Honma, T.; Yokoyama, S. In silico functional profiling of small molecules and its applications. J. Med. Chem. 2008, 51, 7706-7718.
114. Vig, B. S.; Stouch, T. R.; Timoszyk, J. K.; Quan, Y.; Wall, D. A.; Smith, R. L.; Faria, T. N. Human PEPT1 pharmacophore distinguishes dipeptide transport and binding. J. Med. Chem. 2006, 49, 3636-3644.
115. Murcia, M.; Morreale, A.; Ortiz, A. R. Comparative binding energy analysis considering multiple receptors: A step toward 3D QSAR models for multiple targets. J. Med. Chem. 2006, 49, 6241-6253.
116. Zhang, S.; Fernandez, F.; Hazeldine, S.; Deschamps, J.; Zhen, J.; Reith, M. E. A.; Dutta, A. K. Further structural exploration of tri-substituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino- tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: A proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters. J. Med. Chem. 2006, 49, 4239-4247.
117. Pirard, B.; Matter, H. Matrix metalloprotease target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis. J. Med. Chem. 2006, 49, 51-69.
118. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029-5046.
119. Rosenfeld, R. J.; Garcin, E. D.; Panda, K.; Andersson, G.; Åberg, A.; Wallace, A. V.; Morris, G. M.; Olson, A. J.; Stuehr, D. J.; Tainer, J. A.; Getzoff, E. D. Conformational changes in nitric oxide synthases induced by chloroxazone and nitroindazoles: Crystallographic and computational analysis of inhibitor potency. Biochemistry 2002, 41, 13915-13925.
120. Davis, A. M.; St-Galley, S. A.; Kleywegt, J. Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov. Today 2008, 13, 831-841.
121. Hawkins, P. C. D.; Warren, G. L.; Skillman, A. G.; Nicholls, A. How to do an evaluation: pitfalls and traps. J. Comput.-Aided Mol. Des. 2008, 22, 179-190.
122. Verli, H.; Calazans, A.; Brindeiro, R.; Tanuri, A.; Guimarã, J. A. Molecular dynamics analysis of HIV-1 matrix protein: Clarifying differences between crystallographic and solution structures. J. Mol. Graph. Model. 2007, 26, 62-68.
123. Duca, J. S.; Madison, V.S.; Voigt, J. H. Cross-docking of inhibitors into CDK2 structures. 1. J. Chem. Inf. Model. 2008, 48, 659-668.
124. Voigt, J. S.; Elkin, C.; Madison, V. S.; Duca, J. S. Cross-docking of inhibitors into CDK2 structures. 2. J. Chem. Inf. Model. 2008, 48, 669-678.
125. Verdonk, M. L.; Mortenson, P. N.; Hall, R. J.; Hartshorn, M. J.; Murray, C. W. Protein-ligand docking against non-native protein conformers. J. Chem. Inf. Model. 2008, 48, 2214-2225.
126. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: A practical alternative. Curr. Opin. Struct. Biol. 2008, 18, 178-184.
127. Beril, X.; Morley, S. D. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J. Med. Chem. 2005, 48, 4432-4443.
128. Rao, S.; Sanschagrin, P. C.; Greenwood, J. R.; Repasky, M. P.; Sherman, W.; Farid, R. Improving database enrichment through ensemble docking. J. Comput.-Aided Mol. Des. 2008, 22, 621-627.
129. Sutherland, J. J.; Nandigam, R. K.; Erickson, J. A.; Vieth, M. Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy. J. Chem. Inf. Model. 2007, 47, 2293-2302.
130. Cozzini, P.; Kellogg, G. E.; Spyrakis, F.; Abraham, D. J.; Constantino, G.; Emerson, A.; Fanelli, F.; Gohlke, H.; Kuhn, L. A.; Morris, G. M.; Orozco, M.; Pertinhez, T. A.; Rizzi, M.; Sotriffer, C. A. Target flexibility: An emerging consideration in drug discovery and design. J. Med. Chem. 2008, 51, 6237-6255.
131. Cheng, L. S.; Amaro, R. E.; Xu, D.; Li, W. W.; Arzberger, P. W.; McCammon, J. A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 2008, 51, 3878-3894.
132. Claußen, H.; Buning, C.; Rarey, M.; Lengauer, T. FLEXE: Efficient molecular docking considering protein structure variations. J. Mol. Biol. 2001, 308, 377-395.
133. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 2006, 49, 543-553.
134. Schnecke, V.; Kuhn, L. A. Virtual screening with solvation and ligand-induced complementarity. Perspect. Drug Discov. Des. 2000, 20, 171-190.
135. Repo, S.; Jyrkkärinne, J.; Pulkkinen, J. T.; Laatikainen, R.; Honkakoski, P.; Johnson, M. S. Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis. J. Med. Chem. 2008, 51, 7119-7131.
136. Capellacci, L.; Franchetti, P.; Vita, P.; Petrelli, R.; Lavecchia, A.; Jayaram, H. N.; Saiko, P.; Graser, G.; Szekeres, T.; Grifantini, M. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3′-C-methyladenosine derivatives. J. Med. Chem. 2008, 51, 4260-4269.
137. Zhao, X.; Sanner, M. F. Protein-ligand docking with multiple flexible side chains. J. Comput.-Aided Mol. Des. 2008, 22, 673-679.
138. Kokh, D. B.; Wenzel, W. Flexible side chain models improve enrichment rates in in silico screening. J. Med. Chem. 2008, 51, 5919-5931.
139. Hoffman, D.; Kramer, B.; Washio, T.; Steinmetzer, T.; Rarey, M.; Lengauer, T. Two-stage method for protein-ligand docking. J. Med. Chem. 1999, 42, 4422-4433.
140. Yoon, S.; Welsh, W. J. Identification of a minimal subset of receptor conformations for improved multiple conformation docking and two-step scoring. J. Chem. Inf. Comput. Sci. 2004, 44, 88-96.
141. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 2006, 49, 534-553.
142. Luque, I.; Freire, E. Structural stability of binding sites: Consequences for binding affinity and allosteric effects. Proteins 2000, S4, 63-71.
143. Pyrkov, T. V.; Kosinsky, Y. A.; Arseniev, A. S.; Priestle, J. P.; Jacoby, E.; Efremov, R. G. Docking of ATP to Ca-ATPase: Considering protein domain motions. J. Chem. Inf. Model. 2007, 47, 1171-1181.
144. Novak, W.; Wang, H.; Krilov, G. Role of protein flexibility in the design of Bcl-XL targeting agents: Insight from molecular dynamics. J. Comput.-Aided Mol. Des. 2009, 23, 49-61.
145. Amadei, A.; Linssen, A. B. M.; Berendsen, H. J. C. Essential dynamics of proteins. Proteins 1993, 17, 412-425.
146. May, A.; Zacharias, M. Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: Evaluation on kinase inhibitor cross docking. J. Med. Chem. 2008, 51, 3499-3506.
147. Kufareva, I.; Abagyan, R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 2008, 51, 7921-7932.
148. Koska, J.; Spassov, V. Z.; Maynard, A. J.; Yan, L.; Austin, N.; Flook, P. K.; Venkatachalam, C. M. Fully automated mechanics based induced-fit protein-ligand docking method. J. Chem. Inf. Model. 2008, 48, 1965-1973.
149. Corbeil, C. R.; Englebienne, P.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0. J. Med. Chem. 2007, 50, 435-449.
150. Amadasi, A.; Surface, J. A.; Spyrakis, F.; Cozzini, P.; Mozzarelli, A.; Kellogg, G. E. Robust classification of "relevant" water molecules in putative protein binding sites. J. Med. Chem. 2008, 51, 1063-1067.
151. Huang, N.; Shoichet, B. K. Exploiting ordered waters in molecular docking. J. Med. Chem. 2008, 51, 4862-4865.
152. Jones, G.; Willett, P.; Glen, R. C. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J. Comput.-Aided Mol. Des. 1995, 9, 532-549.
153. Richmond, N. J. ; Abrams, C. A.; Wolohan, P. R. N.; Abrahamian, E.; Willett, P.; Clark, R. D. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput.-Aided Mol. Des. 2006, 20, 567-587.
154. Shepphird, J. K.; Clark, R. D. A marriage made in torsional space: Using GALAHAD models to drive pharmacophore multiplet searches. J. Comput.-Aided Mol. Des. 2006, 20, 763-771.
155. Clark, R. D.; Abrahamian, E. A staged multi-objective optimization approach to finding selective pharmacophores. J. Comput.-Aided Molec. Des. 2009 (in press).
156. Dixon, S. L.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.; Friesner, R. A. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput.-Aided Mol. Des. 2006, 20, 647-671.
157. Park, S.-J.; Jung, Y. H.; Kim, Y.-G.; Park, H.-J. Identification of novel ligands for the RNA pseudoknot that regulate -1 ribosomal frameshifting. Bioorg. Med. Chem. 2008, 16, 4676-4684.
158. Ryu, C.-K.; Lee, Y.; Park, S.; You, H.-J.; Lee, R.-Y.; Lee, S.-Y.; Choi, S. 3D QSAR studies of heterocyclic quinines with inhibitory activity on vascular smooth muscle cell proliferation using pharmacophore-based alignment. Bioorg. Med. Chem. 2008, 16, 9772-9779.
159. Andrade, C. H.; Salum, L. de B.; Pasqualoto, K. F. M.; Ferreira, E. I.; Andricopulo, A. D. Three-dimensional quantitative structure-activity relationships for a large series of potent antitubercular agents. Lett. Drug Des. Discov. 2008, 5, 377-387.
160. Long, W.; Liu, P.; Li, Q.; Xu, Y.; Gao, J. 3D-QSAR studies on a class of IKK-2 inhibitors with GALAHAD used to develop molecular alignment models. QSAR Comb. Sci. 2008, 27, 1113-1119.
161. Ferrari, C.; Macchiarulo, A.; Costantino, G.; Pellicciari, R. Pharmacophore model for bile acids recognition by the FPR receptor. J. Comput.-Aided Mol. Des. 2006, 20, 295-303
162. Lather, V.; Kristam, R.; Saini, J. S.; Kristam, R.; Karthikeyan, N. A.; Balaji, V. N. QSAR models for prediction of glycogen synthase kinase-3β inhibitory activity of indirubin derivatives. QSAR Comb. Sci. 2008, 27, 718-728.
163. Gerlach, C.; Broughton, H.; Zaliani, A. FTree query construction for virtual screening: A statistical analysis. J. Comput.-Aided Mol. Des. 2008, 22, 111-118.
164. Wolber, G.; Dornhofer, A. A.; Langer, T. Efficient overlay of small organic molecules using 3D pharmacophores. J. Comput.-Aided Mol. Des. 2006, 20, 773-788.
165. Tervo, A. J.; Rönkkö, T.; Nyrönen, T. H.; Poso, A. BRUTUS: Optimization of a grid-based similarity function for rigid-body molecular superposition. I. Alignment and virtual screening applications. J. Med. Chem. 2005, 48, 4076-4086.
166. Rönkkö, T.; Tervo, A. J.; Parkkinen, J.; Poso, A. BRUTUS: Optimization of a grid-based similarity function for rigid-body molecular superposition. II. Description and characterization. J. Comput.-Aided Mol. Des. 2006, 20, 227-236.
167. Kulkarni, R. G.; Srivani, P.; Achaiah, G.; Sastry, G. N. Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study. J. Comput.-Aided Mol. Des. 2007, 21, 155-166.
168. Hillebrecht, A.; Klebe, G. Use of 3D QSAR models for database screening: A feasibility study. J. Chem. Inf. Model. 2008, 48, 384-396.
169. Clark, R. D.; Leonard, J. M.; Strizhev, A. Pharmacophore models and comparative molecular field analysis (CoMFA). In Pharmacophore Perception, Development, and Use in Drug Design, O. Güner, Ed.; International University Line: La Jolla, CA, 1999; pp. 151-169.
170. Cruciani, G.; Crivori, P.; Carrupt, P.-A.; Testa, B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. 2000, 503, 17-30.
171. Larsen, S. B.; Jørgensen, F. S.; Olsen, L. QSAR models for the human H+/peptide symporter, hPEPT1: Affinity prediction using alignment-independent descriptors. J. Chem. Inf. Model. 2008, 48, 233-241.
172. Low, C. M. R.; Vinter, J. G. Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points. J. Med. Chem. 2008, 51, 565-573.
173. Cheeseright, T. J.; Mackey, M. D.; Melville, J. L.; Vinter, J. G. FieldScreen: Virtual Screening using molecular fields. Application to the DUD data set. J. Chem. Inf. Model. 2008, 48, 2108-2117.
174. Durán, Á.; Martínez, G. C.; Pastor, M. Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in molecular interaction fields. J. Chem. Inf. Model. 2008, 48, 1813-1823.
175. Clark, R. D.; Sprous, D. G.; Leonard , J. M. Validating models based on large data sets. In Rational Approaches to Drug Design, Höltje, H.-D., Sippl, W., Eds.; Prous Science: Barcelona, 2001; pp. 475-485.
176. Clark, R. D. Boosted leave-many-out cross-validation: the effect of training and test set diversity on PLS statistics. J. Comput.-Aided Mol. Des. 2003, 17, 265-275.
177. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidase by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758.
178. Nayana, M. R. S.; Sekhar, Y. N.; Nandyala, H.; Muttineni, R.; Bairy, S. K.; Singh, K.; Mahmood, S. K. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies. J. Mol. Graph. Model. 2008, 27, 233-243.
179. Gupte, A.; Buolameini, J. K. CoMFA and CoMSIA 3D-QSAR studies on S6-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). Bioorg. Med. Chem. Lett. 2009, 19, 314-318.
180. Cramer, R. D.; Clark, R. D.; Patterson, D. E.; Ferguson, A. M. Bioisosterism as a molecular diversity descriptor: Steric fields of single topomeric conformers. J. Med. Chem. 1996, 39, 3060-3069.
181. Cramer, R. D.; Jilek, R.; Guessregen, S.; Clark, S. J.; Wendt, B.; Clark, R. D. "Lead-Hopping". Validation of topomer similarity as a superior predictor of similar biological activities. J. Med. Chem. 2004, 47, 6777-6791.
182. Cramer, R. D.; Cruz, P.; Stahl, G.; Curtiss, W. C.; Campbell, B.; Masek, B. B.; Soltanshahi, F. Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using topomer CoMFA. J. Chem. Inf. Model. 2008, 48, 2180-2195.
183. Shoichet D. Ligand solvation in molecular docking. Proteins 1999, 34, 4-16.
184. Buzko, O. V.; Bishop, A. C.; Shokat, K. M. Modified AutoDock for accurate docking of protein kinase inhibitors. J. Comput.-Aided Mol. Des. 2002, 16, 1573-4951.
185. Deng, W.; Verlinde, C. L. M. J. Evaluation of different virtual screening programs for docking in a charged binding pocket. J. Chem. Inf. Model. 2008, 48, 2010-2020.
186. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2002, 16, 741-753.
187. Tirado-Rives, J.; Jorgensen, W. L. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J. Med. Chem. 2006, 49, 5880-5884.
188. Ruvinsky, A. M. Role of binding entropy in the refinement of protein-ligand docking predictions: Analysis based on the use of 11 scoring functions. J. Comput. Chem. 2007, 28, 1364-1372.
189. Forman-Kay, J. D. The 'dynamics' in the thermodynamics of binding. Nat. Struct. Biol. 1999, 6, 1086-1087.
190. Zidek, L.; Novotny, M. V.; Stone, M. J. Increased protein backbone conformational entropy upon hydrophobic ligand binding. Nat. Struct. Biol. 1999, 6, 1118-1121.
191. Balog, E.; Becker, T.; Oettl, M.; Lechner, R.; Daniel, R.; Finney, J.; Smith, J. C. Direct determination of vibrational density states change on ligand binding to a protein. Phys. Rev. Lett. 2004, 93, 028103.
192. Carbonell, T.; Freire, E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry 2005, 44, 11741-11748.
193. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 2008, 13, 869-874.
194. Bortolato, A.; Moro, S. In silico binding free energy predictability by using the linear interaction energy (LIE) method: Bromobenzimidazole CK2 inhibitors as a case study. J. Chem. Inf. Model. 2007, 47, 572-582.
195. Carlsson, J.; Boukharta, L.; Åqvist, J. Combining docking, scoring, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. J. Med. Chem. 2008, 51, 2648-2656.
196. Nervall, M.; Hanspers, P.; Carlsson, J.; Boukharta, L.; Åqvist, J. Predicting binding modes from free energy calculations. J. Med. Chem. 2008, 51, 2657-2667.
197. Catana, C.; Stouten, P. F. W. Novel, customizable scoring functions, parameterized using N-PLS, for structure-based dug discovery. J. Chem. Inf. Model. 2007, 47, 85-91.
198. Pham, T. A.; Jain, A. N. Customizing scoring functions for docking. J. Comput.-Aided Mol. Des. 2008, 22, 269-286.
199. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
200. Joseph-McCarthy, D.; Alvarez, J. C. Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases. Proteins 2003, 51, 189-202.
201. Goto, J.; Kataoka, R.; Hirayama, N. Ph4Dock: Pharmacophore-based protein-ligand docking. J. Med. Chem. 2004, 44, 6804-6811.
202. Lin, T.-H.; Lin, G.-L. An anchor-dependent molecular docking process for docking flexible small molecules into rigid protein receptors. J. Chem. Inf. Model. 2008, 48, 1638-1655.
203. Deng, Z.; Chuaqui, C.; Singh, J. Structural interaction fingerprint (SIFt): A novel method for analyzing three-dimensional protein-ligand binding interactions. J. Med. Chem. 2004, 47, 337-344.
204. Singh, J.; Deng, Z.; Narale, G.; Chuaqui, C. Structural interaction fingerprints: A new approach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem. Biol. Drug Des. 2006, 67, 5-12.
205. Mpamhanga, C. P.; Chen, B.; McLay, I. M.; Willett, P. Knowledge-based interaction fingerprint scoring: A simple method for improving the effectiveness of fast scoring functions. J. Chem. Inf. Model. 2006, 46, 686-698.
206. Radestock, S.; Weil, T.; Renner, S. Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring. J. Chem. Inf. Model. 2008, 48, 1104-1117.
207. Venhorst, J. V.; Núñez, S.; Terpstra, J. W.; Kruse, C. H. Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. J. Med. Chem. 2008, 51, 3222-3229.
208. Muthas, D.; Sabnis, Y. A.; Lundborg, M.; Karlén, A. Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. J. Mol. Graph. Model. 2008, 26, 1237-1251.
209. Steindl, T. M.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. High-throughput structure-based pharmacophore modeling as a basis for successful parallel screening. J. Comput.-Aided Mol. Des. 2006, 20, 703-715.
210. Zou, J.; Xie, H.-Z.; Yang, S.-Y.; Chen, J.-J.; Ren, J.-X.; Wei, Y.-Q. Towards more accurate pharmacophore modeling: Multiplex-based comprehensive pharmacophore map and most-frequent feature pharmacophore model of CDK2. J. Mol. Graph. Model. 2008, 27, 430-438.
211. Markt, P.; Schuster, D.; Kirchmair, J.; Laggner, C.; Langer, T. Pharmacophore modeling and parallel screening for PPAR ligands. J. Comput.-Aided Mol. Des. 2007, 21, 575-590.
212. Barillari, C.; Marcou, G.; Rognan, D. Hot-spots-guided receptor-based pharmacophores (HS-Pharm): A knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores. J. Chem. Inf. Model. 2008, 48, 1396-1410.
213. Tintori, C.; Corradi, V.; Magnani, M.; Manetti, F.; Botta, M. Targets looking for drugs: A multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J. Chem. Inf. Model. 2008, 48, 2166-2179.
214. Bello, A. M.; Bende, T.; Wei, L.; Wang, X.; Majchrzak-Kita, B.; Fish, E. N.; Kotra, L. P. De novo design of nonpeptidic compounds targeting the interactions between interferon-α and its cognate cell surface receptor. J. Med. Chem. 2008, 51, 2734-2743.
215. Schuster, D.; Nashev, L. G.; Kirchmair, J.; Laggner, C.; Wolber, G.; Langer, T. Discovery of non-steroidal 17β-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J. Med. Chem. 2008, 51, 4188-4199.
216. Markt, P.; Petersen, R. K.; Flindt, E. N.; Kristiansen, K.; Kirchmair, J.; Spitzer, G.; Distinto, S.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. J. Med. Chem. 2008, 51, 6303-6317.
217. Wei, D.; Jiang, X.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J.; Lai, l. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 2008, 51, 7882-7888.
218. Pan, D.; Tseng, Y.; Hopfinger, A. J. Quantitative structure-based design: Formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Chem. Inf. Model. 2003, 43, 1591-1607.
219. Breu, B.; Silber, K.; Gohlke, H. Consensus adaptation of fields for molecular comparison (AFMoC) models incorporate ligand and receptor conformational variability into tailor-made scoring functions. J. Chem. Inf. Model. 2007, 47, 2383-2400.
220. Santos-Filho, O. A.; Cherkasov, A. Using molecular docking, 3D QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest. J. Chem. Inf. Model. 2008, 48, 2054-2065.
221. Cherkasov, A.; Ban, F.; Santos-Filho, O.; Thorsteinson, N.; Fallahi, M.; Hammond, G. L. An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin. J. Med. Chem. 2008, 51, 2047-2056.
222. Johnson, S. L.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D. V.; Strongin, A. Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: Synthesis, SAR, and structure-based 3D QSAR studies. J. Med. Chem. 2006, 49, 27-30.
223. Tuccinardi, V.; Rapposelli, S.; Martinelli, A. Proposal of a new binding orientation for non-peptide AT1 antagonists: Homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. 2006, 49, 4305-4316.
224. Bordas, B.; Belai, I.; Lopata, A.; Szanto, Z. Interpretation of scoring functions using 3D molecular fields, mapping the diacylhydrazine-binding pocket of an insect ecdysone receptor. J. Chem. Inf. Model. 2007, 47, 176-185.
225. Khedkar, S. A.; Malde, A. K.; Coutinho, E. C. Design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3D-QSAR, and de novo design. J. Chem. Inf. Model. 2007, 47, 1839-1846.
226. Honório, K. M.; Garratt, R. C.; Polikarpov, I.; Andricopulo, A. D. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. J. Mol. Graph. Model. 2007, 25, 921-927
227. Muegge, I.; Podlogar, B. L.3D-Quantitative Structure Activity Relationships of Biphenyl Carboxylic Acid MMP-3 Inhibitors: Exploring Automated Docking as Alignment Method. QSAR Comb. Sci. 2008, 20, 215-222.
228. AbdulHameed, M. D. M.; Hamza, A.; Liu, J.; Zhan, C.-G. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1. J. Chem. Inf. Model. 2008, 48, 1760-1772.
229. Salum, L. B.; Polikarpov, I.; Andricopulo, A. D. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. J. Chem. Inf. Model. 2008, 48, 2243-2253.
230. Ivanov, A. A.; Wang, B.; Klutz, A. M.; Chen, V. L.; Gao, Z.-G.; Jacobson, K. A. Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists. J. Med. Chem. 2008, 51, 2088-2099.
231. Nawrozkij, M. B.; Rotili, D.; Tarantino, D.; Botta, G.; Eremiychuk, A. S.; Musmuca, I.; Ragno, R.; Samueke, A.; Zanoli, S.; Armand-Ugón, M.; Clotet-Codina, I.; Novakov, I. A.; Orlinson, B. S.; Maga, G.; Esté, J. A.; Artico, M.; Mai, A. 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl) pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. J. Med. Chem. 2008, 51, 4641-4652.
232. Chen, C. K.-M.; Hudock, M. P.; Zhang, Y.; Guo, R.-T.; Cao, R.; No, J. H.; Liang, P.-H.; Ko, T.-P.; Chang, T.-H.; Chang, S.-c.; Song, Y.; Axelson, J.; Kumar, A.; Wang, A. H.-J.; Oldfield, E. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: A crystallographic and computational investigation. J. Med. Chem. 2008, 51, 5594-5607.
233. Sundriyal, S.; Viswanad, B.; Bharathy, E.; Ramarao, P.; Chakraborti, A. K.; Bharatam, P. V. New PPARγ ligands based on 2-hydroxy-1,4- naphthoquinone: Computer-aided design, synthesis, and receptor-binding studies. Bioorg. Med. Chem. Lett. 2008, 18, 3192-3195.
234. Ma, X.; Zhou, L.; Zuo, Z.-L.; Liu, J.; Yang, M.; Wang, R.-W. Molecular docking and 3-D QSAR of substituted 2,2-bisarylbicycloheptanes as human 5-lipoxygenase-activating protein (FLAP) inhibitors. QSAR Comb. Sci. 2008, 27, 10893-1091.
235. Sheng, C.; Zhang, W.; Ji, H.; Zhang, M.; Song, Y.; Xu, H.; Zhu, J.; Miao, Z.; Jiang, Q.; Yao, J.; Zhou, Y.; Zhu, J.; Lü, J. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. J. Med. Chem. 2006, 49, 2512-2525.
236. Clark, R. D. A ligand's-eye view of protein binding. J. Comput.-Aided Mol. Des. 2008, 22, 507-521.
237. Zhang, Q.; Yang, J.; Liang, K.; Li, S.; Wan, J.; Xu, X.; Yang, G.; Liu, D.; Yang, S. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculations and 3D-QDAR CoMFA modeling. J. Chem. Inf. Model. 2008, 48, 1802-1812.
238. Zhang, T.; Zhou, J.-H.; Shi, L.-W.; Zhu, R.-X.; Chen, M.-B. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett. 2008, 17, 2156-2160.
239. Ortiz, A. R.; Pisabarro, M. T.; Gago, F.; Wade, R. C.; Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem. 1995, 38, 2681-2691.
240. Murcia, M.; Ortiz, A. R. Virtual screening with flexible docking and COMBINE-based models. Application to a series of Factor Xa inhibitors. J. Med. Chem. 2004, 47, 805-820
241. Gohlke, H.; Klebe, G. DrugScore meets CoMFA: Adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J. Med. Chem. 2002, 45, 4153-4170.
242. Silber, K.; Heidler, P.; Kurz, T.; Klebe, G. AFMoC enhances predictivity of 3D QSAR: A case study with DOXP-reductoisomerase. J. Med. Chem. 2005, 48, 3547-3563.
243. Tsai, K.-C.; Chen, S.-Y.; Liang, P.-H.; Lu, I-L.; Mahindroo, N.; Hsieh, H.-P.; Chao, Y.-S.; Liu, L.; Liu, D.; Lien, W.; Lin, T.-H.; Wu, S.-Y. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J. Med. Chem. 2006, 49, 3485-3495.
244. Yu, W.-M.; Guvench, O.; MacKerell, A. D. Jr.; Qu, C.-K. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay. J. Med. Chem. 2008, 51, 7396-7404.
245. Khan, M. T. H.; Fuskevåg; Sylte, I. Discovery of potent thermolysin inhibitors using structure based virtual screening and binding assays. J. Med. Chem. 2009, 52, 48-61.
246. Kovač, A.; Konc, J.; Vehar, B.; Bostock, J. M.; Chopra, I.; Janežič, D.; Gobec, S. Discovery of new inhibitors of D-alanine:D-alanini ligase by virtual screening. J. Med. Chem. 2008, 51, 7442-7448.
247. Park, H.; Bahn, Y. J.; Jung, S.-K.; Jeong, D. G.; Lee, S.-H.; Seo, I.; Yoon, T.-S.; Kim, S. J.; Ryu, S. E. Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. J. Med. Chem. 2008, 51, 5533-5541.
248. Martucci, W. E.; Udier-Blagovic, M..; Atreya, C.; Babatunde, O.; Vargo, M. A.; Jorgensen, W. L.; Anderson, K.S. Novel non-active site inhibitor of Cryptsporidium hominis TS-DHFR identified by a virtual screen. Bioorg. Med. Chem. Lett. 2009, 19, 418-423.
249. Kenyon, V.; Chorny, I.; Carvajal, W. J.; Holman, T. R.; Jacobson, M. P. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J. Med. Chem. 2006, 49, 1356-1363.
250. Herschhorn, A.; Hizi, A. Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. J. Med. Chem. 2008, 51, 5702-5713.
251. Jyrkkäarinne, J.; Windshügel, B.; Rönkko, T.; Tervo, A. J.; Küblbeck, J.; Lahtela-Kakkonen, M.; Sippl, W.; Poso, A.; Honkakoski, P. Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship. J. Med. Chem. 2008, 51, 7181-7192.
252. Geronikaki, A. A.; Lagunin, A. A.; Hadjipavlou-Litina, D. I.; Eleftheriou, P. T.; Filimonov, D. A.; Poroikov, V. V.; Alam, I.; Saxena, A. K. Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. J. Med. Chem. 2008, 51, 1601-1609.
253. Kiss, R.; Kiss, B.; Könczöl, F.; Szalai, F.; Jelinek, I.; László, V.; Noszál, B.; Falus, A.; Keserucombining double acute accent, G. M. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J. Med. Chem. 2008, 51, 3145-3153.
254. Lyne, P. D.; Kenny, P. W.; Cosgrove, D. A.; Deng, C.; Zabludoff, S.; Wendoloski, J. J.; Ashwell, S. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004, 47, 1962-1968.
255. Deng, G.; Li, W.; Shen, J.; Jiang, H.; Chen, K.; Liu, H. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: Virtual screening, synthesis, and biological evaluation. Bioorg. Med. Chem. Lett. 2008, 18, 5497-5502.
256. Cho, Y.; Ioerger, T. R.; Sacchettini, J. Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J. Med. Chem. 2008, 51, 5984-5992.
257. Luo, C.; Xie, P.; Marmorstein, R. Identification of BRAF inhibitors using in silico screening. J. Med. Chem. 2008, 51, 6121-6127.
258. Carosati, E.; Budriesi, R.; Ioan, P.; Ugenti, M. P.; Frosini, M.; Fusi, F.; Corda, G.; Cosimelli, B.; Spinelli, D.; Chiarini, A.; Cruciani, G. Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening. J. Med. Chem. 2008, 51, 5552-5565.
259. Yu, H.; Wang, Z.; Zhang, L.; Zhang, J.; Huang, Q. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 2126-2133.
260. Kim, H.-J.; Doddareddy, M. R.; Choo, H.; Cho, Y. S.; No, K. T.; Park, W.-K.; Pae, A. N. New serotonin 5-HT6 ligands from common feature pharmacophore hypotheses. J. Chem. Inf. Model. 2008, 48, 197-206.
261. Wang, H.; Duffy, R. A.; Boykow, G. C.; Chackalamannil, S.; Madison, V. S. Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. J. Med. Chem. 2008, 51, 2439-2446.
262. Taha, M. O.; Dahabiyeh, L. A.; Bustanji, Y.; Zalloum, H.; Saleh, S. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J. Med. Chem. 2008, 51, 6478-6494.
263. Schuster, D.; Maurer, E. M.; Laggner, C.; Nashev, L. G.; Wilckens, T.; Langer, T.; Odermatt, A. The discovery of new 11β-hydroxycorticosteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J. Med. Chem. 2008, 51, 3454-3466.
264. Rollinger, J. M.; Steindl, T. M.; Schuster, D.; Kirchmair, J.; Anrain, K.; Ellmerer, E. P.; Langer, T.; Stuppner, P.; Schmidtke, M. Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J. Med. Chem. 2008, 51, 842-851.
265. Dayam, R.; Al-Mawasawi, L. Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-carboxylic acid pharmacophore: Design of second-generation HIV-1 integrase inhibitors. J. Med. Chem. 2008, 51, 1136-1144.
266. Tikhhonova, I. G.; Sum, C. S.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. G. Discovery of novel antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J. Med. Chem. 2008, 51, 625-633.
267. Söderholm, A. A.; Viiliäinen, J.; Lehtovuori, P. T.; Eskelinen, H.; Roell, D.; Baniahmad, A.; Nyrönen, T. H. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures. J. Chem. Inf. Model. 2008, 48, 1882-1890.
268. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.
269. Abagyan, R. A.; Totrov, M. M.; Kuznetsov, D. A. ICM: A new method for structure modeling and design. J. Comput. Chem. 1994, 15, 488-506.
270. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
271. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic. J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
272. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759.
273. Jain, A. N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput.-Aided Mol. Des. 2007, 21, 281-306..
274. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
275. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
276. McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, F. K. Gaussian docking functions. Biopolymers 2003, 68, 76-90.
277. Schnecke, V.; Kuhn, L. A. Virtual screening with solvation and ligand-induced complementarity. Perspect. Drug Discov. Des. 2000, 20, 171-190.
278. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
279. Wolber, G.; Thierry Langer, T. LigandScout: 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 2005, 45, 160-169
280. Chen, J.; Lai, L. H. Pocket v.2: Further developments on receptor-based pharmacophore modeling. J. Chem. Inf. Model. 2006, 46, 2684-2691